PRospective Evaluation of Interstitial Lung DIsease Progression With Quantitative CT

Enrolling by invitationOBSERVATIONAL
Enrollment

54

Participants

Timeline

Start Date

June 1, 2023

Primary Completion Date

October 31, 2024

Study Completion Date

October 31, 2024

Conditions
Interstitial Lung Disease
Interventions
DIAGNOSTIC_TEST

HRCT Thorax

HRCT Thorax at 0, 6 and 12 months

DEVICE

Glycocheck Endothelial Glycocalyx Assessment

Measure of EG degradation using GlycoCheck Microvascular Health Score at 0, 6 and 12 months

DIAGNOSTIC_TEST

Blood biomarkers

Endothelial glycocalyx degradation blood biomarkers and angiogenesis markers at 0, 6 and 12 months

DIAGNOSTIC_TEST

Peripheral leucocyte telomere length

HT-STELA (High-throughput single telomere length assessment) at 0, 6 and 12 months

DIAGNOSTIC_TEST

Pulmonary function testing

Pulmonary Function Tests (Spirometry and Gas Transfer) and 6-minute walk distance at 0, 6 and 12 months

DIAGNOSTIC_TEST

Patient reported outcome measures

Electronic collection of patient reported outcome measures

Trial Locations (1)

Unknown

University of Exeter Medical School, Exeter

All Listed Sponsors
collaborator

North Bristol NHS Trust

OTHER

collaborator

Royal United Hospitals Bath NHS Foundation Trust

OTHER

collaborator

Royal Devon and Exeter NHS Foundation Trust

OTHER

lead

University of Exeter

OTHER